Discover how modern immunotherapy awakens T cells to shrink melanoma tumors, tracked by PET scans and used after surgery to prevent relapse. In this segment, Dr. Morrison provides clinical context ...

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung ...

Key market opportunities include rising cancer prevalence, technological advances in infusion systems, and expanding ...

Pharmac is widening access to two melanoma medicines, giving cancer patients more funded immunotherapy options.

Add Yahoo as a preferred source to see more of our stories on Google. Spencer Laird at Duke Cancer Center in 2025 Doctors are optimistic about his remission, calling his progress "uncharted territory" ...

Pharmac will widen access to two melanoma medicines, giving New Zealanders another funded immunotherapy option and reducing the amount of treatment some people may need. From 1 May 2026, people with ...

A young dad named Spencer Laird was diagnosed with colon cancer around age 26, but was treated with a surgery that removed 16 inches of his colon. Because of this, and the fact that two years had ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Anne Jordan was diagnosed with blood cancer in 2016. After multiple treatments of chemotherapy and radiation, her doctors recommended she consult Dr. Nakhle Saba, director of the CAR-T program at ...

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to ...